SCHEDULE: Armistice Capital Discloses Vivos Therapeutics Stake

Armistice Capital, LLC and Steven Boyd have reported beneficial ownership of 8.27% of Vivos Therapeutics, Inc. common stock as of March 31, 2026.

Summary

• Armistice Capital, LLC, acting as the investment manager for Armistice Capital Master Fund Ltd., and Steven Boyd, the managing member of Armistice Capital, have jointly filed a Schedule 13G.
• This filing indicates beneficial ownership of 1,115,859 shares of Vivos Therapeutics, Inc. common stock.
• This ownership represents 8.27% of the total class of securities.
• The reporting date for this ownership is March 31, 2026.
• Armistice Capital exercises voting and investment power over the securities held by the Master Fund.
• Steven Boyd may be deemed to beneficially own these securities due to his role at Armistice Capital.
• The Master Fund disclaims beneficial ownership due to its Investment Management Agreement with Armistice Capital.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It's a standard disclosure of ownership and does not inherently contain positive or negative operational news about Vivos Therapeutics.

Positives

• Significant stake of 8.27% in Vivos Therapeutics, Inc. common stock reported by Armistice Capital and Steven Boyd.
• Clear disclosure of beneficial ownership, providing transparency to the market.

Negatives

• The Master Fund disclaims beneficial ownership of the shares it directly holds, which could indicate a complex ownership structure or specific contractual limitations.

Risks

• Potential for increased market activity or influence by Armistice Capital given their 8.27% stake.
• The disclaimer of beneficial ownership by the Master Fund might suggest underlying complexities or potential future disputes regarding control or voting rights.

Future Outlook

No specific forward-looking statements or guidance were provided in this Schedule 13G filing, which is primarily an ownership disclosure.

Management Comments

• Armistice Capital, LLC exercises voting and investment power over the securities of the Issuer held by the Master Fund and thus may be deemed to beneficially own the securities of the Issuer held by the Master Fund.
• Mr. Boyd, as the managing member of Armistice Capital, may be deemed to beneficially own the securities of the Issuer held by the Master Fund.
• The Master Fund specifically disclaims beneficial ownership of the securities of the Issuer directly held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice Capital.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are standard for institutional investors and significant shareholders to disclose their holdings. This filing indicates a notable stake by Armistice Capital in Vivos Therapeutics, which could signal increased investor interest or potential strategic involvement.

Stakeholder Impact

• Shareholders: Increased transparency regarding a significant beneficial owner, potentially influencing market perception and trading activity.
• Management of Vivos Therapeutics: Awareness of a substantial shareholder with shared voting and disposition power, which may necessitate engagement or consideration in strategic decisions.

Next Steps

• Monitor future filings from Armistice Capital and Steven Boyd for any changes in their beneficial ownership of Vivos Therapeutics, Inc. stock.
• Observe Vivos Therapeutics, Inc. for any strategic announcements or developments that may be influenced by this significant shareholder position.

Key Dates

Keywords

Schedule 13G, Vivos Therapeutics, Armistice Capital, Steven Boyd, Beneficial Ownership, Common Stock, SEC Filing, Investment Management